DXCM DexCom, Inc.
Healthcare$72.10+0.28%ClosedMarket Cap: $27.82B
As of 2026-05-25
Valuation
P/E (TTM)
29.86
PEG
0.66
P/B
9.39
P/S
5.77
EV/EBITDA
21.73
DCF Value
$34.50
FCF Yield
5.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
61.8%
Operating Margin
21.4%
Net Margin
19.3%
ROE
33.8%
ROA
14.0%
ROIC
18.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.19B | 62.9% | $255.3M | $199.5M | $— | — |
| Q4 null | $1.26B | 62.9% | $323.0M | $267.3M | $— | — |
| FY null | $4.66B | 60.0% | $911.8M | $836.3M | $— | — |
| Q3 null | $1.21B | 61.8% | $242.5M | $283.8M | $— | — |
| Q2 null | $1.16B | 59.5% | $212.6M | $179.8M | $— | — |
| Q1 null | $1.04B | 56.9% | $133.7M | $105.4M | $— | — |
| Q4 null | $1.11B | 58.9% | $188.9M | $151.7M | $— | — |
| FY null | $4.03B | 60.5% | $600.0M | $576.2M | $— | — |
| Q3 null | $994.2M | 59.7% | $152.0M | $134.6M | $— | — |
| Q2 null | $1.00B | 62.4% | $158.0M | $143.5M | $— | — |
| Q1 null | $921.0M | 61.0% | $101.1M | $146.4M | $— | — |
| Q4 2023 | $1.03B | 63.5% | $216.9M | $256.3M | $0.62 | — |